Bio-Techne Corporation announced Matthew F. McManus has been appointed President, Diagnostics and Genomics Segment, effective January 8, 2024. Dr. McManus succeeds Kim Kelderman, who will become Bio-Techne's Chief Executive Officer effective February 1, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
80.91 USD | +1.71% | +4.68% | +4.86% |
May. 06 | Argus Adjusts Price Target on Bio-Techne to $95 From $90, Keeps Buy Rating | MT |
May. 02 | UBS Adjusts Price Target on Bio-Techne to $90 From $80, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.86% | 12.75B | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+27.29% | 12.06B | |
-3.50% | 11.75B | |
+20.18% | 11.72B |
- Stock Market
- Equities
- TECH Stock
- News Bio-Techne Corporation
- Bio-Techne Corporation Appoints Kim Kelderman as Chief Executive Officer Effective February 1, 2024